Terumo (TRUMY)
(Delayed Data from OTC)
$17.43 USD
-0.22 (-1.25%)
Updated Jul 23, 2024 03:59 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRUMY 17.43 -0.22(-1.25%)
Will TRUMY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TRUMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRUMY
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
Terumo (TRUMY) Moves to Strong Buy: Rationale Behind the Upgrade
TRUMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for March 28th
New Strong Buy Stocks for March 28th
Here's What Could Help Terumo Corp. (TRUMY) Maintain Its Recent Price Strength
Other News for TRUMY
MicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms
MicroVention Announces Settlement Against Former Employees for Trade Secret Misappropriation and Breach of Contract Among Other Claims
MicroVention Announces Clinical Publication of SOFAST: SOFIA™ Aspiration System as First Line Technique in Treating Acute Ischemic Stroke
MicroVention Announces the Next Evolution in Stent Innovation: MicroVention’s LVIS™ EVO™ Intraluminal Support Device Now Available in the United States
Data-Driven Growth Fuels More Upside For Overlooked Artivion